Company: ZVRA
Filing Date: 2025-04-21
Form Type: DEFA14A
Source: 0001193125-25-086311
Chunk: 9

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-04-21
Form: DEFA14A
Chunk 9
---
Myers Squibb, senior Vice President of Marketing at Merck, and executive management positions at West Pharmaceuticals, Osteotech, and Centocor, in addition to roles at SmithKline and French (now GlaxoSmithKline) in marketing, regulatory 
 affairs, project management, and as a biochemist.                                                                                                                                                                                                    |
| Tamara A. Favorito has served as a director and Chair of the Audit Committee since August 2021, and as our Board Chair since May 2023. Ms. Favorito has more than 30 years of industry experience, including 20 years as a                           
 Chief Financial Officer for multiple publicly-traded life science companies, including Immunic, Inc., Signal Genetics, Inc. (now Viridian Therapeutics, Inc.), and Favrille, Inc. (now MMR Global, Inc.). Ms. Favorito is the only director who was  
 on the Board prior to 2023, giving her a deeper understanding of the Company’s history and an important perspective as the Company continues its path forward.                                                                                       |

Mangless’ Proposal to Add a Proxy Solicitor and a Former CEO with Value- Destructive Track Records Meaningfully Risks Disruption to Zevra’s Continued Execution of its Strategic Plan Mr. Mangless is proposing to replace two of your highly-qualified directors with his two nominees. Neither of Mr. Mangless’ nominees would bring any additive skills or experience to the Board. We have significant concerns about the potential disruption and distraction Mr. Mangless’ nominees could bring to Zevra’s operations. More specifically:

| • |     | Mr. Mangless’ nominee, Mr. Regan, runs a five-person proxy solicitation firm, has no industry                                                                                                                                             
 experience or expertise in life sciences, and is distinctly ill-suited to serve as a director of a leading commercial rare disease company like Zevra. Mr. Regan’s only experience as a director of a                                     
 public operating company was over 25 years ago at US Wats, Inc. (“US Wats”), a telecommunications company where he served as corporate secretary and director. As of April 2000, subsequent to a merger, US Wats appears to have abruptly 
 ceased complying with its reporting requirements, a responsibility that seems directly tied to Mr. Regan as the company’s corporate secretary and director at that time, and the company’s SEC registration was subsequently revoked.     
 Furthermore, during Mr. Regan’s tenure as a director, US Wats stockholder